Clinical trials with oncolytic adenovirus in China

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 141-148

  Yu, Wang ^a,b   Fang, Hu ^a  

^a Shanghai Sunway Biotech Co Ltd   (China)

^b GanTai Plaza ^*  (China)

Author keywords

Adenovirus; China; Clinical trial; H101; Oncolytic virus

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; E1B PROTEIN; FLUOROURACIL; H 101; H 103; ONCOLYTIC ADENOVIRUS; ONYX 015; UNCLASSIFIED DRUG;

ALOPECIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HUMAN; INJECTION SITE PAIN; LEUKOPENIA; LIVER DYSFUNCTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PENIS CARCINOMA; REVIEW; SARCOMA; SIDE EFFECT; THROMBOCYTE; TUMOR VOLUME; VIRUS PARTICLE;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ADENOVIRUS E3 PROTEINS; ADULT; AGED; CHINA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; RESEARCH DESIGN; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33847389767     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058817     Document Type: Review

References (42)

1. Ezzeddine, Z. D.; Martuza, R. L.; Platika, D.; Short, M. P.; Malick, A.; Choi, B.; Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991, 3, 608-614.
2. Ganly, I.; Kirn, D.; Eckhardt, G.; Rodriguez, G. I.; Soutar, D. S.; Otto, R.; Robertson, A. G.; Park, O.; Gulley, M. L.; Heise, C.; Von Hoff, D. D.; Kaye, S. B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000, 6, 798-806.
3. Kaplan, J. M. Adenovirus-based cancer gene therapy. Curr. Gene Ther. 2005, 5, 595-605.
4. Van den Heuvel, S. J.; van Laar, T.; Kast, W. M.; Melief, C. J.; Zantema, A.; van der Eb, A. J. Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Adtransformed cells. EMBO J. 1990, 9, 2621-2629.
5. Harada, J. N.; Berk, A. J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 1999, 73, 5333-5344.
6. O'Shea, C. C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6, 611-623.
7. Nemunaitis, J.; Ganly, I.; Khuri, F.; Arseneau, J.; Kuhn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000, 60, 6359-6366.
8. Mulvihill, S.; Warren, R.; Venook, A.; Adler, A.; Randlev, B.; Heise, C.; Kirn, D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 2001, 8, 308-315.
9. Galanis, E.; Okuno, S. H.; Nascimento, A. G.; Lewis, B. D.; Lee, R. A.; Oliveira, A. M.; Sloan, J. A.; Atherton, P.; Edmonson, J. H.; Erlichman, C.; Randlev, B.;Wang, Q.; Freeman, S.; Rubin, J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005, 12, 437-445.
10. Chiocca, E. A.; Abbed, K. M.; Tatter, S.; Louis, D. N.; Hochberg, F. H.; Barker, F.; Kracher, J.; Grossman, S. A.; Fisher, J. D.; Carson, K.; Rosenblum, M.; Mikkelsen, T.; Olson, J.; Markert, J.; Rosenfeld, S.; Nabors, L. B.; Brem, S.; Phuphanich, S.; Freeman, S.; Kaplan, R.; Zwiebel, J. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 2004, 10, 958-966.
11. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Andrews, J.; Romel, L.; Hatfield, M.; Rubin, J.; Kirn, D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001, 8, 1618-1626.
12. Vasey, P. A.; Shulman, L. N.; Campos, S.; Davis, J.; Gore, M.; Johnston, S.; Kirn, D. H.; O'Neill, V.; Siddiqui, N.; Seiden, M. V.; Kaye, S. B. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 2002, 20, 1562-1569.
13. Makower, D.; Rozenblit, A.; Kaufman, H.; Edelman, M.; Lane, M. E.; Zwiebel, J.; Haynes, H.; Wadler, S. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 2003, 9, 693-702.
14. Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Bruso, P.; Kaye, S. B.; Hong, W. K.; Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000, 6, 879-885.
15. Lamont, J. P.; Nemunaitis, J.; Kuhn, J. A.; Landers, S. A.; McCarty, T. M. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 2000, 7, 588-592.
16. Yuan, Z. Y.; Zhang, L.; Li, S.; Qian, X. Z.; Guan, Z. Z. [Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer]. Ai Zheng 2003, 22, 310-313.
17. Xu, R. H.; Yuan, Z. Y.; Guan, Z. Z.; Cao, Y.; Wang, H. Q.; Hu, X. H.; Feng, J. F.; Zhang, Y.; Li, F.; Chen, Z. T.; Wang, J. J.; Huang, J. J.; Zhou, Q. H.; Song, S. T. [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer]. Ai Zheng 2003, 22, 1307-1310.
18. Xia, Z. J.; Chang, J. H.; Zhang, L.; Jiang, W. Q.; Guan, Z. Z.; Liu, J. W.; Zhang, Y.; Hu, X. H.; Wu, G. H.; Wang, H. Q.; Chen, Z. C.; Chen, J. C.; Zhou, Q. H.; Lu, J. W.; Fan, Q. X.; Huang, J. J.; Zheng, X. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai Zheng 2004, 23, 1666-1670.
19. O'Shea, C. C.; Soria, C.; Bagus, B.; McCormick, F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005, 8, 61-74.
20. Rosell, R.; Gatzemeier, U.; Betticher, D. C.; Keppler, U.; Macha, H. N.; Pirker, R.; Berthet, P.; Breau, J. L.; Lianes, P.; Nicholson, M.; Ardizzoni, A.; Chemaissani, A.; Bogaerts, J.; Gallant, G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. 2002, 13,1539-1549.
21. Grigorescu, A. C.; Draghici, I. N.; Nitipir, C.; Gutulescu, N.; Corlan, E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 2002, 37, 9-14.
22. Gridelli, C.; Ardizzoni, A.; Le Chevalier, T.; Manegold, C.; Perrone, F.; Thatcher, N.; van Zandwijk, N.; Di Maio, M.; Martelli, O.; De Marinis, F. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. 2004, 15, 419-426.
23. Cappello, F.; Ribbene, A.; Campanella, C.; Czarnecka, A. M.; Anzalone, R.; Bucchieri, F.; Palma, A.; Zummo, G. The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review. Eur. J. Histochem. 2006, 50, 25-34.
24. Cappello, F.; David, S.; Rappa, F.; Bucchieri, F,; Marasa, L.; Bartolotta, T. E.; Farina, F.; Zummo, G. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 2005, 5, 139.
25. Wang, X. Y.; Li, Y.; Yang, G.; Subjeck, J. R. Current ideas about applications of heat shock proteins in vaccine design and immunotherapy. Int. J. Hyperthermia 2005, 21, 717-722.
26. Huang, X. F.; Ren, W.; Rollins, L.; Pittman, P.; Shah, M.; Shen, L.; Gu, Q.; Strube, R.; Hu, F.; Chen, S. Y. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 2003, 63, 7321-7329.
27. Liu, X. Y.; Gu, J. F. Targeting gene-virotherapy of cancer. Cell Res. 2006, 16, 25-30.
28. Liu, X. Y.; Qiu, S. B.; Zou, W. G.; Pei, Z. F.; Gu, J. F.; Luo, C. X.; Ruan, H. M.; Chen, Y.; Qi, Y. P.; Qian, C. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol. Ther. 2005, 11, 531-541.
29. Pei, Z.; Chu, L.; Zou, W.; Zhang, Z.; Qiu, S.; Qi, R.; Gu, J.; Qian, C.; Liu, X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004, 39, 1371-1381.
30. Zhang, Z.; Zou, W.; Wang, J.; Gu, J.; Dang, Y.; Li, B.; Zhao, L.; Qian, C.; Qian, Q.; Liu, X. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol. Ther. 2005, 11, 553-562.
31. Zhao, L.; Gu, J.; Dong, A.; Zhang, Y.; Zhong, L.; He, L.; Wang, Y.; Zhang, J.; Zhang, Z.; Huiwang, J.; Qian, Q.; Qian, C.; Liu, X. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum. Gene Ther. 2005, 16, 845-858.
32. Qiu, S.; Ruan, H.; Pei, Z.; Hu, B.; Lan, P.; Wang, J.; Zhang, Z.; Gu, J.; Sun, L.; Qian, C.; Liu, X.; Qi, Y. Combination of targeting gene-virotherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma. J. Interferon Cytokine Res. 2004, 24, 219-230.
33. Zhang, Z. L.; Zou, W. G.; Luo, C. X.; Li, B. H.; Wang, J. H.; Sun, L. Y.; Qian, Q. J.; Liu, X. Y. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003, 13, 481-489.
34. Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98, 298-300.
35. Jia, H.; Kling, J. China offers alternative gateway for experimental drugs. Nat. Biotechnol. 2006, 24, 117-118.
36. Louet, S. Can China bring its own pipeline to the market? Nat. Biotechnol. 2004, 22, 1497-1499.
37. Kirn, D. H. The end of the beginning: Oncolytic virotherapy achieves clinical proof-of-concept. Mol. Ther. 2006, 13, 237-238.
38. Wu, J. T.; Kirn, D. H.; Wein, L. M. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull. Math. Biol. 2004, 66, 605-625.
39. Wein, L. M.; Wu, J. T.; Kirn, D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 2003, 63, 1317-1324.
40. Yuan, Z. Y.; Guan, Z. Z.; Zhang, L.; Xu, R. H. [Effect of expression of coxsackie and adenovirus receptor on antitumor activity of genetically modified adenovirus]. Ai Zheng 2005, 24, 502-505.
41. McCormick, F. Future prospects for oncolytic therapy. Oncogene 2005, 24, 7817-7819.
42. Shi, H.; Cao, T.; Connolly, J. E.; Monnet, L.; Bennett, L.; Chapel, S.; Bagnis, C.; Mannoni, P.; Davoust, J.; Palucka, A. K.; Banchereau, J. Hyperthermia enhances CTL cross-priming. J. Immunol. 2006, 176, 2134-2141.